Lilly's Phase 3b trial shows Zepbound combined with Taltz delivers 40% better skin clearance in psoriasis patients. GLP-1s prove value beyond weight loss.

Lilly Proves Zepbound Boosts Psoriasis Treatment: GLP-1s Expand Beyond Weight Loss

Eli Lilly pays up to $2.4B for Orna Therapeutics' circular RNA platform to develop in vivo CAR-T therapies for autoimmune diseases. The fourth major pharma deal in this space.

Eli Lilly Pays Up to $2.4 Billion for Orna Therapeutics, Joining In Vivo CAR-T Race

Eli Lilly pays Innovent $350M upfront with $8.5B in potential milestones for oncology and immunology drug development rights—their 7th collaboration.

Eli Lilly Deepens China Bet with $8.85B Innovent Oncology and Immunology Deal

TrumpRx.gov launches with 43 discounted drugs from 5 pharma giants. Wegovy drops to $199/mo, Zepbound to $299/mo. GLP-1 stocks extend losses.

TrumpRx Goes Live: GLP-1 Drug Prices Slashed Up to 85%, Pharma Stocks React

Eli Lilly Q4 revenue surges 43% to $19.3B, crushing estimates by 7%. Mounjaro and Zepbound sales double. 2026 guidance of $80-83B stuns Street.

Eli Lilly Crushes Q4 as Mounjaro and Zepbound Sales Double—Stock Surges 8%

Eli Lilly announces $3.5B Pennsylvania plant to make retatrutide, its triple-agonist obesity drug showing 24% weight loss in trials.

Eli Lilly Bets $3.5 Billion on Pennsylvania to Build Retatrutide Arsenal

ELI LILLY & (LLY) Earnings Call Transcripts

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Q2 2024

Q1 2024

Q4 2023

Q3 2023

Q2 2023

Recent News about ELI LILLY &